Animal models for novel therapies on fibrosis and NASH

Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach.

Hypoxia; Lung fibrosis; PET/CT; [18F]FDG; [18F]FMISO.

Discovery of Novel Inhibitors of PIM-1 Kinase Enabled by Generative AI

Use generative AI to generate and identify new PIM-1 kinase inhibitor hits with activity, freedom-to-operate, and good in vitro ADME properties.

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

Novel approaches in drug discovery using innovative models (PDX & PDX-derived models) to better mimic the situation of the human cancer pathologies.

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance

Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).

Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1

Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.

Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment

In this study we describe establishment of a luminal breast cancer PDX model with acquired resistance to hormonotherapy

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection